We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
-0.2%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$279M
AUM Growth
-$15.1M
(-5.1%)
Cap. Flow
-$10.5M
Cap. Flow
% of AUM
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
54.03%
Holding
87
New
14
Increased
26
Reduced
16
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
+$4.5M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$3.48M |
| 3 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$3.39M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$2.97M |
| 5 |
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
|
+$2.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$5.49M |
| 2 |
Curis
CRIS
|
+$3.95M |
| 3 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
+$2.96M |
| 4 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
+$2.54M |
| 5 |
Celldex Therapeutics
CLDX
|
+$2.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.7% |
| 2 | Financials | 3.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$15.9B
| $33.5M | 12% |
550,000
-27,500
| -5% | -$1.57M |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $27.1M | 9.69% |
+200,000
| New | +$26.3M |
|
3
PUT
ARK Genomic Revolution ETF
ARKG
$1.61B
| $20.8M | 7.45% |
225,000
-15,000
| -6% | -$1.28M |
|
|
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.1M | 5.06% |
246,201
+51,201
| +26% | +$2.82M |
|
|
CVAC
5
PUT
DELISTED
CureVac
CVAC
| $11M | 3.95% |
+150,000
| New | +$15M |
|
|
VINC
6
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $10.9M | 3.9% |
41,916
+14,765
| +54% | +$4.5M |
|
7
Nautilus Biotechnolgy
NAUT
$221M
| $9.09M | 3.25% |
900,000
+211,000
| +31% | +$2.29M |
|
8
Kura Oncology
KURA
$964M
| $8.86M | 3.17% |
425,000
+60,000
| +16% | +$1.49M |
|
|
NARI
9
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $7.93M | 2.84% |
85,000
+35,000
| +70% | +$3.39M |
|
|
10
Zentalis Pharmaceuticals
ZNTL
$364M
| $7.58M | 2.71% |
142,418
+64,918
| +84% | +$3.48M |
|
|
ARYD
11
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $7.5M | 2.69% |
700,000
| – | – |
|
|
XLRN
12
DELISTED
Acceleron Pharma
XLRN
| $6.9M | 2.47% |
55,000
+10,000
| +22% | +$1.26M |
|
|
13
Protagonist Therapeutics
PTGX
$9.06B
| $6.29M | 2.25% |
140,100
+90,100
| +180% | +$2.97M |
|
14
Rocket Pharmaceuticals
RCKT
$376M
| $5.32M | 1.9% |
120,000
+35,000
| +41% | +$1.52M |
|
|
15
Curis
CRIS
$9.02M
| $5.25M | 1.88% |
1,625
-875
| -35% | -$3.95M |
|
|
CERE
16
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $5.12M | 1.83% |
200,000
-70,000
| -26% | -$1M |
|
17
Aclaris Therapeutics
ACRS
$793M
| $4.83M | 1.73% |
275,000
+52,733
| +24% | +$1.2M |
|
18
CALL
Alnylam Pharmaceuticals
ALNY
$35.7B
| $4.24M | 1.52% |
+25,000
| New | +$3.66M |
|
19
Ocular Therapeutix
OCUL
$1.96B
| $3.54M | 1.27% |
250,000
+22,500
| +10% | +$342K |
|
20
Orchestra BioMed
OBIO
$220M
| $3.06M | 1.1% |
300,000
+75,000
| +33% | +$776K |
|
21
CALL
Ionis Pharmaceuticals
IONS
$8.99B
| $2.99M | 1.07% |
+75,000
| New | +$2.94M |
|
22
CALL
Moderna
MRNA
$24.5B
| $2.94M | 1.05% |
12,500
+7,500
| +150% | +$1.34M |
|
|
MSAC
23
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $2.9M | 1.04% |
+300,000
| New | +$2.93M |
|
|
KDNY
24
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.82M | 1.01% |
200,000
+25,000
| +14% | +$400K |
|
25
Pulmonx
LUNG
$59.1M
| $2.65M | 0.95% |
60,000
+15,000
| +33% | +$653K |
|
Similar funds
FM
1SB
HCL
OCM
MWA
AF
NFG
HC
Affinity Asset Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, Affinity Asset Advisors held 87 positions worth $279M, down 5.1% from $294M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Affinity Asset Advisors withdrew a net $10.5M in Q2 2021, closing 18 positions and reducing 16 holdings. Its most notable exit was Travere Therapeutics, an estimated $5.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.
Against the trend, Affinity Asset Advisors opened a new position in Medicus Sciences Acquisition Corp. Class A Ordinary Share worth $2.9M.
- Affinity Asset Advisors's largest Q2 2021 buy was Medicus Sciences Acquisition Corp. Class A Ordinary Share: 300,000 shares worth $2.9M.
- Affinity Asset Advisors added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $4.5M increase.
- Affinity Asset Advisors's biggest Q2 2021 reduction was Curis, cutting an estimated $3.95M.
- Affinity Asset Advisors fully exited Travere Therapeutics in Q2 2021, selling an estimated $5.49M.
- Affinity Asset Advisors's ten largest holdings make up 54% of its $279M portfolio in Q2 2021.
- Affinity Asset Advisors opened 14 new positions and closed 18 in Q2 2021.
- Affinity Asset Advisors's portfolio value fell 5.1% quarter-over-quarter to $279M.
Based on Affinity Asset Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.